Program
Sodium Fluoride
Also written as “NaF”, “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash” and “0.022% Sodium Fluoride mouthwash”.
Its studies are mostly in Gingivitis · Tooth Erosion · Tooth Discoloration · Dental Plaque · Dentin Sensitivity, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 110 open or running | phase 3since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| Colgate Palmolive | 30 open or running | phase 3since Jun 27, 2024 | Jun 27, 2024 | none ahead |
| Procter and Gamble | 10 open or running | phase 2since Mar 19, 2025 | Mar 19, 2025 | none ahead |
| Protegera | 10 open or running | early phase 1since Oct 4, 2023 | Oct 4, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2008First studies: 3 phase 3 studiesNew to GlaxoSmithKlineGlaxoSmithKline · NCT00708305, NCT00708123, NCT00708097
- Oct 15, 2009Phase 3 study in CariesGlaxoSmithKline · NCT01005966 · 65 enrolled
- Apr 30, 2010Phase 2 study in Tooth ErosionGlaxoSmithKline · NCT01128972 · 36 enrolled · United States
- Jul 12, 2012Phase 3 study in Enamel ErosionGlaxoSmithKline · NCT01641237 · 72 enrolled · United States
- Aug 2, 2012No phase study in Tooth ErosionGlaxoSmithKline · NCT01657903 · 56 enrolled · United States
- Jul 17, 2014No phase study in Oral HygieneGlaxoSmithKline · NCT02195583 · 62 enrolled · United States
- Jul 21, 20142 phase 2 studies in Oral HygieneGlaxoSmithKline · NCT02207400, NCT02207907
- Aug 25, 2014Phase 2 study in Dentin SensitivityGlaxoSmithKline · NCT02226562 · 191 enrolled · United States
- Oct 4, 2023Protegera's first study: early phase 1 study in Dental PlaqueNew to ProtegeraProtegera · NCT06082869 · 82 enrolled · United States
- Jun 27, 2024Colgate Palmolive's first study: phase 3 study in Tooth DiscolorationNew to Colgate PalmoliveColgate Palmolive · NCT06486974 · 80 enrolled · Dominican Republic
- Mar 19, 2025Procter and Gamble's first study: phase 2 study in GingivitisNew to Procter and GambleProcter and Gamble · NCT06892834 · 120 enrolled · Canada
- Nov 24, 2025Phase 3 study in GingivitisColgate Palmolive · NCT07263698 · 80 enrolled · Italy
- Jan 27, 2026Phase 3 study in Plaque, AmyloidColgate Palmolive · NCT07398846 · 134 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07398846Plaque, Amyloid · United States | 3 | Completed | Colgate Palmolive | Apr 29, 2026 | 134 |
| NCT07263698Gingivitis · Italy | 3 | Completed | Colgate Palmolive | Feb 27, 2026 | 80 |
| NCT06892834Gingivitis · Canada | 2 | Completed | Procter and Gamble | Jun 19, 2025 | 120 |
| NCT06486974Tooth Discoloration · Dominican Republic | 3 | Completed | Colgate Palmolive | Nov 8, 2024 | 80 |
| NCT06082869Dental Plaque · United States | Early 1 | Completed | Protegera | Feb 23, 2023 | 82 |
| NCT02226562Dentin Sensitivity · United States | 2 | Completed | GlaxoSmithKline | Dec 1, 2014 | 191 |
| NCT02207907Oral Hygiene · United States | 2 | Completed | GlaxoSmithKline | Feb 2015 | 247 |
| NCT02207400Oral Hygiene · United States | 2 | Completed | GlaxoSmithKline | Feb 1, 2015 | 246 |
| NCT02195583Oral Hygiene · United States | – | Completed | GlaxoSmithKline | Aug 2014 | 62 |
| NCT01657903Tooth Erosion · United States | – | Completed | GlaxoSmithKline | Feb 2012 | 56 |
| NCT01641237Enamel Erosion · United States | 3 | Completed | GlaxoSmithKline | May 2012 | 72 |
| NCT01128972Tooth Erosion · United States | 2 | Completed | GlaxoSmithKline | Oct 2009 | 36 |
| NCT01005966Caries | 3 | Completed | GlaxoSmithKline | Mar 2009 | 65 |
| NCT00708305Dental Caries · United States | 3 | Completed | GlaxoSmithKline | Oct 2008 | 65 |
| NCT00708123Healthy Subjects | 3 | Completed | GlaxoSmithKline | Apr 2008 | 60 |
| NCT00708097Caries · United States | 3 | Completed | GlaxoSmithKline | Jul 2008 | 57 |
How it is read
Names in the registry
- “NaF”, 2 entries
- “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”, 1 entry
- “0.022% Sodium Fluoride mouthwash”, 1 entry
- “Sodium Fluoride Dentifrice”, 1 entry
- “Protegera™ toothpaste (NaF)”, 1 entry
Conditions, from the studies’ own filings
- Gingivitis, 3 studies
- Tooth Erosion, 2 studies
- Tooth Discoloration, 1 study
- Dental Plaque, 1 study
- Dentin Sensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.